Comparison
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189 vs 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Fetal Androgens Excess and 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
A condition where an XX fetus produces excess male hormones, often from adrenal gland abnormalities, leading to atypical genital development. It is identified at birth. Treatment typically includes hormone therapy and possible surgery.
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
A rare condition affecting how certain hormones are processed in the body, which can influence sexual development. Treatment may involve hormone therapy and specialist care.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
0-0
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
0-16
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
severe
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
Chronic
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
No
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
reproductive
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
endocrine
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
endocrine
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
endocrine
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-fetal-androgens-excess-C5680189 and 3-oxo-5-alpha-steroid-delta-4-dehydrogenase-deficiency-C0268297 differ in severity
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189 | 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 | Discriminating power |
|---|---|---|---|
| Genital appearance | Atypical or virilized external genitalia in an XX fetus, often noted at birth. | Variable under- or atypical virilization; recognition may be delayed until puberty. | Moderate |
| Timing of recognition | Source onset is at birth (0–0). | Source onset spans birth to age 16. | High |
| Primary system emphasis | Reproductive development with possible adrenal androgen excess. | Endocrine hormone processing affecting sexual development. | Moderate |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189 when
XX infant with atypical genitalia at birth
Matches fetal androgen excess and birth-only onset in the source.
Moderate
Suspected adrenal source of androgen excess
Source specifically links the condition to adrenal abnormalities, though not every cause is proven.
Moderate
Severe congenital genital difference
Source severity is severe rather than moderate.
Low
Choose 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 when
Findings emerge or clarify during childhood or puberty
Source allows onset through age 16, unlike birth-only left onset.
Moderate
Enzyme-related hormone-processing disorder is suspected
The concept names a steroid dehydrogenase deficiency rather than fetal androgen excess.
Moderate
Moderate endocrine phenotype without established adrenal crisis
Source rates severity moderate and system endocrine; adrenal disease is not established.
Low
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189 | 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 | Interpretation |
|---|---|---|---|
| Karyotype | 46,XX by definition of the named disorder. | Karyotype is not specified in the source and must be confirmed. | An XX result supports the left concept; it does not by itself prove the enzyme deficiency. |
| Adrenal androgen evaluation | May be abnormal when an adrenal cause is present; no cutoff is supplied. | Not established as the primary abnormality. | Abnormal adrenal results suggest a cause of fetal androgen excess, not a diagnosis alone. |
| Steroid enzyme pathway studies | Pattern depends on the specific adrenal or androgen source. | Aimed at the named dehydrogenase pathway; exact ratios are not supplied. | Specialist biochemical or genetic testing is needed; results require clinical correlation. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Fetal Androgens Excess C5680189
- Outcome
- Chronic and source-rated severe; specific survival or fertility outcomes are not established.
- Factors
- Underlying adrenal or androgen cause, early recognition, and complications.
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
- Outcome
- Chronic and source-rated moderate; long-term outcome is not established.
- Factors
- Degree of hormone-processing impairment and timing of recognition.
Time frame: From birth, with possible reassessment through adolescence.
Exact diagnosis, karyotype, hormone results, and individual response to specialist care.
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal instability | Possible with some adrenal causes, but not established for every case. Not described in the source. Urgent adrenal assessment belongs to suspected adrenal disease, not automatically to the enzyme deficiency. |
| Atypical pubertal development | Ongoing androgen effects may occur; exact course is not supplied. Hormone-processing effects may become clearer around puberty. Neither condition has a universal symptom list in the source. |
| Fertility and surgical considerations | Possible surgery and hormone therapy are mentioned, without indications or doses. Hormone therapy and specialist care may be used; fertility outcome is not established. Decisions are individualized and not determined by these labels alone. |
Patient education highlights
- HighThese are not routine test labels
An abnormal hormone result or genital finding needs specialist interpretation and is not itself a complete diagnosis.
- HighUrgent symptoms
Poor feeding, vomiting, dehydration, or collapse in an infant requires emergency care, especially if adrenal disease is possible.
- MediumLong-term care
Both are described as chronic and may involve hormone therapy; treatment choices, timing, and surgery require shared specialist decision-making.